Stifel sees AtkinsRealis outperforming peers despite potential near-term headwinds

Stifel says AtkinsRealis trades at an 18.5x 2027 P/E premium versus Stantec at 16.9x and WSP Global at 15.4x, while its Q1 2026 adjusted EBITDA estimate of $225 million is 6% below the $238 million consensus. Full-year 2026 EBITDA of $1.184 billion is in line with expectations, but Nuclear backlog may remain temporarily weak until new awards arrive in 2H 2026. Despite near-term volatility and the premium valuation, Stifel would consider buying the stock on weakness given the Nuclear outlook and underleveraged balance sheet.

Analysis

The setup is less about absolute fundamentals and more about relative expectation risk: the market is implicitly paying up for AtkinsRealis’s nuclear optionality while giving the peers credit for steadier infrastructure earnings. That makes STN and WSP vulnerable to multiple compression if investors rotate toward the cleaner “non-nuclear” earnings paths, but it also means any disappointment in AtkinsRealis can rebound into the group through sentiment spillover rather than direct fundamentals.

The more important second-order issue is timing. Near-term weakness in backlog is a months-long sequencing problem, not a broken thesis, but the market tends to penalize visible order gaps before it rewards later contract wins. If nuclear awards slip from second-half 2026 into 2027, the premium multiple becomes hard to defend; if awards land on schedule, the current gap between valuation and growth could narrow quickly as investors price in a multi-year backlog reset.

Contrarian take: the consensus may be underestimating how little downside there is in the balance-sheet story for the better-capitalized name. In a tape where cyclicals are being de-rated, a levered-but-liquid compounder with a credible nuclear pipeline can outperform on a “duration” basis even while reported backlog looks soft. The risk is that this only works if contract timing remains intact; a single quarter of weaker bookings could trigger a 10-15% derating before fundamentals have time to catch up.

Key Decisions for Investors

• Long ATRL / short STN or WSP.TO into any 1-2 week pullback in the group; the trade is for multiple divergence rather than fundamental collapse, with a 6-12 month horizon and best payoff if nuclear award visibility improves into H2 2026.
• Buy ATRL on weakness only after a backlog-driven selloff of 5-8%; risk/reward improves materially there because the market is likely to over-discount timing risk before contract awards arrive.
• For higher-conviction expression, use ATRL call spreads targeting the next 6-9 months: limited premium outlay captures re-rating if backlog fears prove temporary, while capping downside if awards slip.
• If holding STN or WSP.TO, tighten risk ahead of the next earnings cycle; these names are exposed to a valuation reset if investors decide the sector deserves lower multiples despite stable full-year numbers.
• Watch for a second-half 2026 contract announcement window; that is the catalyst that could unwind any pair trade quickly, so stage profits aggressively if award momentum appears.